Concurrent TP53 mutations with KRAS and EGFR are reported as negative prognostic markers for advanced NSCLC patients who are candidates for EGFR-TKI or ALK-TKI treatments (32). This evidence concerns the gene TP53 and non-small cell lung carcinoma.